Yunami Yamada
Overview
Explore the profile of Yunami Yamada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamada Y, Iihara H, Nagano A, Fujii H, Tsugita M, Hoshino R, et al.
Support Care Cancer
. 2025 Mar;
33(4):274.
PMID: 40074887
Background: Doxorubicin and ifosfamide (AI) therapy for soft tissue sarcomas (STS) is given as a 5-day continuous-dose chemotherapy regimen, and classified as carrying high emetic risk. The purpose of this...
2.
Fujii H, Yamada Y, Iihara H, Kobayashi R, Suzuki A
Anticancer Res
. 2025 Mar;
45(3):865-881.
PMID: 40037850
Cancer cachexia, a systemic multifactorial syndrome that affects survival prognosis, occurs in 80% of patients with advanced cancer. Patients with cancer cachexia experience progressive functional disability and persistent loss of...
3.
Fujii H, Makiyama A, Nishimura K, Iihara H, Hirose C, Ohata K, et al.
J Pharm Health Care Sci
. 2024 Jul;
10(1):36.
PMID: 38987837
Background: Anamorelin is expected to improve cancer cachexia by increasing lean body mass (LBM) due to increased appetite and protein synthesis. However, the effect of anamorelin on cancer cachexia in...
4.
Yamada Y, Kobayashi R, Yamamoto T, Fujii H, Iihara H, Hiroko K, et al.
J Pharm Health Care Sci
. 2024 Apr;
10(1):19.
PMID: 38671535
Background: Medication errors related to the pre-admission medication history obtained on admission are a major cause of medication error during hospitalization. Medication reconciliation (MR) improves patient safety through the detection...
5.
Fujii H, Yamada Y, Iihara H, Suzuki A
Asia Pac J Oncol Nurs
. 2024 Jan;
10(Suppl 1):100280.
PMID: 38197038
Cancer cachexia is a complex syndrome, and multidisciplinary management has the potential to improve patient outcomes and efficiency of care. Multidisciplinary management consists primarily of exercise, nutrition, and pharmacotherapy. The...
6.
Yamamoto S, Fujii H, Murayama K, Iihara H, Watanabe D, Yamada Y, et al.
Anticancer Res
. 2023 Nov;
43(11):5099-5105.
PMID: 37909957
Background/aim: Metastatic colorectal cancer (mCRC) is mainly a disease of the elderly. The aim of this retrospective study was to investigate the efficacy and safety of oxaliplatin-based regimens as first-line...
7.
Watanabe D, Fujii H, Yamada Y, Matsuhashi N, Makiyama A, Iihara H, et al.
Int J Clin Oncol
. 2021 Apr;
26(7):1257-1263.
PMID: 33839963
Background: Regorafenib is recognized as a later-line standard treatment in patients with metastatic colorectal cancer (mCRC). In this study, we examined the association of the albumin-bilirubin (ALBI) score in patients...
8.
Yamada Y, Matsuhashi N, Fujii H, Makiyama A, Iihara H, Takahashi T, et al.
Anticancer Res
. 2021 Jan;
41(1):533-541.
PMID: 33419853
Background/aim: We compared the efficacy and safety of second-line FOLFIRI with bevacizumab (Bmab) or aflibercept (AFL) in patients with unresectable metastatic colorectal cancer (mCRC) to clarify selection criteria for anti-angiogenic...
9.
Dose Adjustment of Oxaliplatin Based on Renal Function in Patients With Metastatic Colorectal Cancer
Watanabe D, Fujii H, Matsuhashi N, Iihara H, Yamada Y, Ishihara T, et al.
Anticancer Res
. 2020 Apr;
40(4):2379-2386.
PMID: 32234941
Background/aim: The effect of renal dysfunction on the toxicity and efficacy of oxaliplatin remains unclear. We investigated the association between creatinine clearance (Ccr), a marker of renal function, and the...
10.
Fujii H, Matsuhashi N, Kitahora M, Takahashi T, Hirose C, Iihara H, et al.
Oncologist
. 2020 Mar;
25(3):e469-e476.
PMID: 32162797
Objective: TAS-102 is effective for treating patients with metastatic colorectal cancer (mCRC). This study determined whether combining bevacizumab (Bmab) with TAS-102 improves clinical outcomes in refractory mCRC. Patients And Methods:...